Pharmacyclics, Inc. (NASDAQ:PCYC) today provided its preliminary unaudited 2014 U.S. net product revenue results and 2015 U.S. net product revenue outlook at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. For the fiscal year ended December 31, 2014, U.S. net product revenue for IMBRUVICA® (ibrutinib) is expected to be approximately $492 million. For the fourth quarter of 2014, U.S. net product revenue is expected to be approximately $185 million, which would represent an approximately 31% sequential increase compared to the quarter ended September 30, 2014… Read more

Shares of Pharmacyclics opened today at $123.71 . PCYC has a 1-year high of $154.89 and a 1-year low of $82.51. The stock’s 50-day moving average is $130.92 and it’s 200-day moving average is $120.28.

In total, one research analyst has assigned a Hold rating and 4 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $123.71 which is 27.7% above where the stock opened today.

Pharmacyclics Inc is a biopharmaceutical company engaged in designing, developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.